xBxBio Files U.S. Provisional Patent Application for xBxBio's Virtual Heart™

IRVINE, Calif. - Rezul -- xBxBio today announced that it has filed a U.S. provisional patent application relating to xBxBio's Virtual Heart™, marking an important milestone in the company's intellectual-property and cardiovascular-technology development strategy.

xBxBio's Virtual Heart™ is being developed as part of the company's broader vision for Connected Cardiovascular Intelligence™. Its long-term purpose is to support a more patient-centered and longitudinal understanding of cardiovascular information while keeping clinicians at the center of assessment, interpretation, and decision-making.

The provisional patent application establishes an early filing milestone while allowing xBxBio to continue its research, engineering, scientific evaluation, validation planning, and intellectual-property development.

More on Rezul News

• New Metallized PE Film from Pregis Brings Recyclability to High-Barrier Food Packaging at Pack Expo International in Chicago
• Transformational $104 Million Musculoskeletal Healthcare Opportunity as Expansion Strategy Accelerates for Cardiff Lexington Corp (Stock Symbol: CDIX)
• PropAccount.com Launches Marketing Hub Within PropGenie, Giving Prop Firm Operators an Automated Marketing Team
• Peach Hill Townhomes Selects Corner Property Management AAMC as Community Management Partner
• Save 15 Percent Off Florida Keys Accommodations with KeysCaribbean's Advance Purchase Rate Discount

To protect its confidential and proprietary information, xBxBio is not publicly disclosing the invention's technical architecture, algorithms, computational methods, model designs, implementation details, development materials, patent claims, or other enabling information.

"Filing this provisional patent application is an important step in protecting the innovation associated with xBxBio's Virtual Heart™," said an xBxBio spokesperson. "Our objective is to advance patient-specific cardiovascular intelligence responsibly, with scientific rigor, clinical relevance, traceability, human oversight, and respect for the physician-patient relationship."

xBxBio's work is guided by the principle that cardiovascular information should be understood in the context of the individual patient and evaluated across time. The company's ultimate purpose is to help clinicians consider patient-specific evidence as they develop individualized recommendations.

The company will continue protecting its intellectual property while sharing appropriate non-confidential information about its scientific principles, governance framework, validation approach, and development progress.

More on Rezul News

• Woodside Rehab & Nursing Enters a New Era of Clinical Excellence and Growth
• Thar Process Partners with French Leader ExtrateX to Bring Prep to Process-Scale SFC to Europe
• Arizona Elder Fraud Losses Topped $343 Million in 2025, Advocates Say
• 303 Crown Maids Updates Deep Cleaning Service Page to Reset and Revitalize Homes
• Port St. Lucie REALTOR® Irene Pernice Earns SFR® Certification

A provisional patent application is an initial filing and is not an issued patent. Filing does not mean that the invention has been examined, approved, or granted patent protection by the United States Patent and Trademark Office.

xBxBio's Virtual Heart™ remains under development. It has not been authorized or cleared for clinical use and is not intended to replace professional medical judgment.

About xBxBio

xBxBio is developing Connected Cardiovascular Intelligence™ to help bring fragmented cardiovascular information into a more connected, contextual, longitudinal, and clinically meaningful environment.

The company focuses on cardiovascular informatics, multimodal information, clinical artificial intelligence, healthcare interoperability, data integrity, provenance, validation, governance, and responsible human oversight.

xBxBio views artificial intelligence as a means of strengthening clinical intelligence—not replacing accountable healthcare professionals.

Learn more about xBxBio:
https://xbxbio.com